Review of NICE Technology Appraisal Guidance No. 64; Human growth hormone (somatropin) in adults with growth hormone deficiency

The Institute was proposing that the guidance should be moved to the static list.

During consultation, the majority of comments received by the Institute agreed with the proposal put forward.  After consideration of all of the comments (attached as appendix A), the Institute’s Guidance Executive has decided to proceed with the proposal.

Consequently, TA64 will be moved to the static list of technology appraisals. Topics on the static list can be considered for review if any new evidence becomes available that is likely to lead to a change in the existing recommendations.

November 2014

Attachments

• Appendix A: Decision paper presented to the Institute’s Guidance Executive